42Z Stock Chart & Stats
€131.50
€0.80(1.92%)
At close: 4:00 PM EST
€131.50
€0.80(1.92%)
Day’s Range― - ―
52-Week Range€29.60 - €160.65
Previous CloseN/A
Volume0.00
Average Volume (3M)639.00
Market Cap
€35.16B
Enterprise Value€33.54B
Total Cash (Recent Filing)€1.91B
Total Debt (Recent Filing)€437.27M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 12, 2026EPS Estimate
-1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.11
Shares Outstanding212,596,470
10 Day Avg. Volume1,415
30 Day Avg. Volume639
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€165.20Price Target Upside25.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-6.94
Revenue Forecast (FY)€91.38M
Bulls Say, Bears Say
Bulls Say
Practice‑changing Phase III EfficacyA highly significant Phase III OS benefit materially raises the probability of regulatory approval and rapid uptake in a high‑unmet oncology indication. This durable clinical differentiation strengthens market position, supports future revenue/milestone capture, and underpins commercial launch planning.
Very Strong Pro‑forma LiquidityA multi‑billion dollar cash buffer materially reduces near‑term financings risk and enables execution of multiple registrational programs, global filings and commercial build. This balance sheet strength provides lasting optionality to invest, partner, or scale launches without immediate capital stress.
Diversified Registrational PipelineProgress across several registrational programs and modalities reduces single‑asset binary risk and creates multiple commercialization paths. A broad, advancing pipeline increases the odds of sustained product revenues, partnership leverage and strategic flexibility over the coming years.
Bears Say
Zero Revenue, Heavy And Worsening Cash BurnSustained zero product revenue and very large negative cash flow mean the business relies on capital markets or partners to fund operations. Even with recent raises, persistent high burn and negative returns on equity can erode shareholder value and constrain long‑term strategy if approvals or commercial revenues are delayed.
Materially Higher Operating Cost Base And Stock CompA permanently elevated operating footprint and much larger stock‑based compensation program raise ongoing cash requirements and dilution risk. Higher structural costs reduce financial flexibility, lengthen path to breakeven and increase the likelihood of future financing or reprioritization of programs.
Trial Design And Crossover Complexity RiskWhen an investigational drug becomes new standard, subsequent registrational trials may be harder to design and interpret, risking delays, increased sample sizes or compromised endpoints. These enduring operational and regulatory complexities can slow label expansions and compress expected timelines for additional approvals.
Revolution Medicines News
42Z FAQ
What was Revolution Medicines, Inc.’s price range in the past 12 months?
Revolution Medicines, Inc. lowest stock price was €29.60 and its highest was €160.65 in the past 12 months.
What is Revolution Medicines, Inc.’s market cap?
Revolution Medicines, Inc.’s market cap is €35.16B.
When is Revolution Medicines, Inc.’s upcoming earnings report date?
Revolution Medicines, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.
How were Revolution Medicines, Inc.’s earnings last quarter?
Revolution Medicines, Inc. released its earnings results on May 06, 2026. The company reported -€2.001 earnings per share for the quarter, missing the consensus estimate of -€1.604 by -€0.397.
Is Revolution Medicines, Inc. overvalued?
According to Wall Street analysts Revolution Medicines, Inc.’s price is currently Undervalued.
Does Revolution Medicines, Inc. pay dividends?
Revolution Medicines, Inc. does not currently pay dividends.
What is Revolution Medicines, Inc.’s EPS estimate?
Revolution Medicines, Inc.’s EPS estimate is -1.71.
How many shares outstanding does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has 212,596,470 shares outstanding.
What happened to Revolution Medicines, Inc.’s price movement after its last earnings report?
Revolution Medicines, Inc. reported an EPS of -€2.001 in its last earnings report, missing expectations of -€1.604. Following the earnings report the stock price went up 0.353%.
Which hedge fund is a major shareholder of Revolution Medicines, Inc.?
Currently, no hedge funds are holding shares in DE:42Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€165.20 (25.63% Upside)
€165.20 (25.63% Upside)
Blogger Sentiment
Bullish
DE:42Z Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
408.84%
12-Months-Change
Fundamentals
Return on Equity
-83.22%
Trailing 12-Months
Asset Growth
-4.72%
Trailing 12-Months
Company Description
Revolution Medicines, Inc.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
42Z Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and strategic progress—most notably the practice‑changing RASolute 302 Phase III result (60% reduction in risk of death) and a large capital raise that materially strengthens the balance sheet—while candidly disclosing near‑term financial impacts from rapid program acceleration, elevated stock‑based compensation and higher operating expenses. Operational and regulatory timing uncertainties and trial design complexities were noted, but the program momentum, supportive data across multiple assets, and strong funding availability suggest the positives materially outweigh the headwinds.View all DE:42Z earnings summaries42Z Stock 12 Month Forecast
Average Price Target
€165.20
▲(25.63% Upside)
Technical Analysis
Options Prices
Currently, No data available
---